Literature DB >> 19467918

Advances in understanding of toxicities of treatment for head and neck cancer.

Richard M Logan1.   

Abstract

Toxicities associated with head and neck cancer treatment are common events. Despite the fact that many side effects of cancer treatment are now well controlled, some, such as mucositis and salivary gland hypofunction, continue to be almost inevitable outcomes of cancer treatment. Furthermore, improvements in cancer treatment itself as well as new modalities, such as targeted treatments, may be associated with different toxicities. In this review, common toxicities associated with head and neck cancer treatment will be discussed including those reported to occur with targeted therapies. This review also considers the concept of toxicity clusters, risk factors for toxicity (for example genetics) and individualisation of cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19467918     DOI: 10.1016/j.oraloncology.2009.03.018

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  7 in total

Review 1.  Tumor control versus adverse events with targeted anticancer therapies.

Authors:  Dorothy M K Keefe; Emma H Bateman
Journal:  Nat Rev Clin Oncol       Date:  2011-12-20       Impact factor: 66.675

2.  Microbubble therapy enhances anti-tumor properties of cisplatin and cetuximab in vitro and in vivo.

Authors:  Cara H Heath; Anna Sorace; Joseph Knowles; Eben Rosenthal; Kenneth Hoyt
Journal:  Otolaryngol Head Neck Surg       Date:  2012-02-08       Impact factor: 3.497

3.  Burden, quality of life, and social support in caregivers of patients undergoing radiotherapy for head and neck cancer: A pilot study.

Authors:  Chandylen L Nightingale; Barbara A Curbow; John R Wingard; Deidre B Pereira; Giselle D Carnaby
Journal:  Chronic Illn       Date:  2016-04-10

4.  Cohort study of oncologic emergencies in patients with head and neck cancer.

Authors:  Cielito C Reyes-Gibby; Stephanie C Melkonian; Ehab Y Hanna; Sai-Ching J Yeung; Charles Lu; Mark S Chambers; Srinivas R Banala; Gary B Gunn; Sanjay S Shete
Journal:  Head Neck       Date:  2017-03-27       Impact factor: 3.821

5.  Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms.

Authors:  Jhon A Ochoa-Alvarez; Harini Krishnan; John G Pastorino; Evan Nevel; David Kephart; Joseph J Lee; Edward P Retzbach; Yongquan Shen; Mahnaz Fatahzadeh; Soly Baredes; Evelyne Kalyoussef; Masaru Honma; Martin E Adelson; Mika K Kaneko; Yukinari Kato; Mary Ann Young; Lisa Deluca-Rapone; Alan J Shienbaum; Kingsley Yin; Lasse D Jensen; Gary S Goldberg
Journal:  Oncotarget       Date:  2015-04-20

6.  Experiences of Head and Neck Cancer Patients in Middle Adulthood: Consequences and Coping.

Authors:  Kathryn Grattan; Catherine Kubrak; Vera Caine; Dan A O'Connell; Karin Olson
Journal:  Glob Qual Nurs Res       Date:  2018-03-15

Review 7.  Genome stability pathways in head and neck cancers.

Authors:  Glenn Jenkins; Kenneth J O'Byrne; Benedict Panizza; Derek J Richard
Journal:  Int J Genomics       Date:  2013-11-04       Impact factor: 2.326

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.